期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 75, 期 2, 页码 141-146出版社
SPRINGER JAPAN KK
DOI: 10.1007/BF02982018
关键词
aplastic anemia; bone marrow transplantation; cyclophosphamide; antithymocyte globulin; graft rejection
类别
资金
- NCI NIH HHS [CA 78902, P01 CA078902] Funding Source: Medline
- NHLBI NIH HHS [HL 36444, HL 63457] Funding Source: Medline
- NIDDK NIH HHS [DK02753] Funding Source: Medline
Survival of patients with aplastic anemia treated with transplantation of bone marrow has improved significantly over the past several decades. Allogeneic bone marrow transplantation (BMT) for patients with HLA-identical siblings is now the first-line therapy, and long-term survival of approximately 90% can be expected with cyclophosphamide/antithlymocyte globulin conditioning and postgrafting methotrexate/cyclosporine immunosuppression. The outcome of unrelated donor BMT has also improved significantly with the identification of a preparative regimen with less toxicity combined with the development of high-resolution DNA-based HLA typing to identify the optimal unrelated marrow donor. Patients with fully HLA-matched unrelated donors should be considered candidates for transplantation prior to exposure to repeat courses of immunosuppression. Future progress in hematopoietic stem cell transplantation for aplastic anemia will be directed toward further decreasing the acute toxicity and decreasing the delayed effects of the conditioning regimens while maintaining highly reliable rates of sustained engraftment with prevention of acute and chronic graft-versus-host disease. Int J Heinatol. 2002;75:141-146. (C)2002 The Japanese Society of Hematology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据